Pregled bibliografske jedinice broj: 917938
Monoamine oxidase A gene methylation and its role in Posttraumatic Stress Disorder – First evidence from the South Eastern Europe (SEE)- PTSD study
Monoamine oxidase A gene methylation and its role in Posttraumatic Stress Disorder – First evidence from the South Eastern Europe (SEE)- PTSD study // International journal of neuropsychopharmacology, 21 (2017), 5; 423-432 doi:10.1093/ijnp/pyx111 (podatak o recenziji nije dostupan, članak, ostalo)
CROSBI ID: 917938 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Monoamine oxidase A gene methylation and its role
in Posttraumatic Stress Disorder – First evidence
from the South Eastern Europe (SEE)- PTSD study
Autori
Ziegler, C. ; Wolf, C. ; Schiele, MA. ; .... Marjanović, Damir ; ....... ; Dzubur-Kulenovic, A ; Deckert, J. ; Domschke, K.
Izvornik
International journal of neuropsychopharmacology (1461-1457) 21
(2017), 5;
423-432
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, ostalo
Ključne riječi
CAPS ; DNA methylation ; MAOA ; PTSD ; epigenetics
Sažetak
BACKGROUND: Posttraumatic Stress Disorder (PTSD) is characterized by an overactive noradrenergic system conferring core PTSD symptoms such as hyperarousal and re-experiencing. Monoamine oxidase A (MAO-A) is one of the key enzymes mediating the turnover of noradrenaline. Here, DNA methylation of the MAOA gene exonI/intronI region was investigated for the first time in regards to its role in PTSD risk and severity. METHODS: MAOA methylation was analyzed via direct sequencing of sodium bisulfite treated DNA extracted from blood cells in a total sample of N=652 (m=441) patients with current PTSD, patients with remitted PTSD and healthy probands (comparison group) recruited at five centres in Bosnia-Herzegovina, Croatia, and the Republic of Kosovo. PTSD severity was measured by means of the Clinician-Administered PTSD Scale (CAPS) and its respective subscores representing distinct symptom clusters. RESULTS: In the male, but not the female sample, patients with current PTSD displayed hypermethylation of three CpGs (CpG3=43, 656, 362 ; CpG12=43, 656, 514 ; CpG13=43, 656, 553, GRCh38.p2 Assembly) as compared to remitted PTSD patients and healthy probands. Symptom severity (CAPS scores) in male patients with current PTSD significantly correlated with MAOA methylation. This applied particularly to symptom clusters related to re- experiencing of trauma (cluster 'B') and hyperarousal (cluster 'D'). CONCLUSIONS: The present findings suggest MAOA gene hypermethylation - potentially resulting in enhanced noradrenergic signalling - as a disease status and severity marker of current PTSD in males. If replicated, MAOA hypermethylation might serve as a surrogate marker of a hyperadrenergic subtype of PTSD guiding personalized treatment decisions on the use of anti-adrenergic agents.
Izvorni jezik
Engleski
Znanstvena područja
Biologija, Temeljne medicinske znanosti
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE
